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Abstract
Background: The aim of this study was to investigate the profile of antibodies against several antigens of
Plasmodium vivax and Plasmodium falciparum in Mandalay, Myanmar.
Methods: Malaria parasites were identified by microscopic examination. To test the antibodies against P. vivax and
P. falciparum in sera, an indirect immunofluorescence antibody test (IFAT) was performed using asexual blood
parasite antigens. An enzyme-linked immunosorbent assay (ELISA) was performed with circumsporozoite protein
(CSP), Pvs25 and Pvs28 recombinant proteins of transmission-blocking vaccine candidates for P. vivax, and liver
stage specific antigen-1 and -3 (PfLSA-1, PfLSA-3) for P. falciparum.
Results: Fourteen patients among 112 were found to be infected with P. vivax and 26 with P. falciparum by thick
smear examination. Twenty-three patients were found to be infected with P. vivax, 19 with P. falciparum and five
with both by thin smear examination. Blood samples were divided into two groups: Group I consisted of patients
who were positive for infection by microscopic examination, and Group II consisted of those who showed
symptoms, but were negative in microscopic examination. In P. falciparum, IgG against the blood stage antigen in
Group I (80.8%) was higher than in Group II (70.0%). In P. vivax, IgG against the blood stage antigen in Group I
(53.8%) was higher than in Group II (41.7%). However, the positivity rate of the PvCSP VK210 subtype in Group II
(40.0%) was higher than in Group I (23.1%). Similarly for the PvCSP VK247 subtype, Group II (21.7%) was higher
than that for Group I (9.6%). A similar pattern was observed in the ELISA using Pvs25 and Pvs28: positive rates of
Group II were higher than those for Group I. However, those differences were not shown significant in statistics.
Conclusions: The positive rates for blood stage antigens of P. falciparum were higher in Group I than in Group II,
but the positive rates for antigens of other stages (PfLSA-1 and -3) showed opposite results. Similar to P. falciparum,
the positive rate of pre-blood stage (CSP VK210 and 247 subtype) and post-blood stage (Pvs25 and 28) antigens of
P. vivax were higher in Group II than in Group I. Therefore, sero-diagnosis is not helpful to discriminate between
malaria patients and symptomatic individuals during the epidemic season in Myanmar.
Background
Malaria constitutes a major health problem and is
strongly associated with socioeconomic ramifications in
many temperate and most tropical countries. In Myan-
mar, malaria is ranked as the number one public health
problem, and nearly 600,000 malaria patients seek
medical attention at health institutions annually. Among
malaria species in Myanmar, Plasmodium falciparum
accounts for approximately 80% of infections and Plas-
modium vivax for 17.8% of infections, whereas the
remaining infections are due to Plasmodium malariae
or mixed infections [1].
The sporozoites of malaria parasites are transmitted
from the saliva of infected mosquitoes and stay for a
while at the site of infection or travel to the liver and
invade hepatocytes, where they develop into the
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any medium, provided the original work is properly cited.exoerythrocytic stage called tissue schizont. During this
stage, the parasites express liver stage-specific antigens.
In P. falciparum, at least two of the relevant antigens,
liver stage antigen-1 (PfLSA-1) and liver stage antigen-3
(PfLSA-3), have been identified and characterized [2-4].
These proteins are both surface proteins, are expressed
solely in infected hepatocytes, and are thought to play a
role in liver schizogony and merozoite release. Specific
humoral, cellular, and cytokine immune responses to
PfLSA-1 and PfLSA-3 are well documented, with identi-
fied epitopes that correlate with antibody production,
proliferative T-cell responses, or cytokine induction
[3-5]. Both pre-erythrocytic antigens have been consid-
ered as vaccine candidates against P. falciparum due to
their antigenic and protective immunogenic properties
[6-9]. In the present study, the levels of antibodies
acquired against P. falciparum LSA-1 and LSA-3 in
inhabitants of Myanmar were monitored to determine
the prevalence of this parasite.
The surface membrane of all Plasmodium sporozoites
is covered by an antigen, the circumsporozoite protein
(CSP). CSP has a central immunodominant region, con-
sisting of tandem repeats of short amino acid sequences,
which contain multiple copies of the immunodominant
B cell epitope [10]. Because CSP is highly immunogenic
and can induce a protective response in sporozoite-
immunized experimental animals and in humans, it is
being investigated as a candidate for a human malaria
vaccine. These immunodominant B cell epitopes of a
large number of P. falciparum isolates of diverse geo-
graphical origin and a smaller number of P. vivax iso-
lates were examined and were found to be conserved
among species [11]. Two groups were identified: the
dominant VK210 subtype and variant form VK247
subtype. A strain of P. vivax containing a variant
repeat in its CSP was first isolated in Thailand [12].
The repeat of this variant strain (Thai VK247) differs
at 6-9 amino acids within the repeat sequence found
in all previously described P. vivax CSP. Following this
discovery, several studies were conducted to evaluate
the global distribution of the VK247 variant; it was
detected in indigenous populations of China [13], Bra-
zil [14], Mexico [15,16], Peru [16,17], and Papua New
Guinea [15]. Evaluating the proportion of CSP sub-
types in Myanmar will be helpful to design future vac-
cine applications based on CSP.
Pvs25 and Pvs28 from P. vivax, which were cloned
from the Sal I strain, have four evolutionarily conserved
tandem epidermal growth factor (EGF)-like domains
attached to the parasite surface by a glycosylphosphati-
dylinositol (GPI) anchor. Antibodies against these pro-
teins have the ability to block parasite formation in
infected mosquitoes. These proteins have been investi-
gated as transmission-blocking vaccines to induce an
immune response in the human host that inhibits the
formation of ookinetes or oocysts in malaria vectors and
consequently preventing the transmission of parasites
from mosquitoes to humans [18].
Additionally, an indirect fluorescent antibody test
(IFAT) was used to analyse the antibodies in blood sam-
ples because serological data can provide additional evi-
dence as to the extent and degree of malaria endemicity
and reflect the period of the infection [19]. Serological
surveys have provided valuable epidemiological informa-
tion, especially in areas with low endemicity [20]. The
rate of parasitaemia is the classical method for measur-
ing the endemicity of malaria, whereas the incidence of
parasitaemia alone can completely fail to provide an
adequate description of a malaria situation in a popula-
tion. When the incidence of malaria is low, mass blood
surveys do not yield results commensurate with the
work involved [21]. Therefore, the application of IFAT
could reflect the situation in the population [22].
Methods
Study areas and blood sample collection
The study was conducted in Sedaw Gyi, Kyauk Me, Pyin
Oo Lwin, and Wet Won in Mandalay, Myanmar, in
June 2004. Sedaw Gyi is located 25 miles to the north
(Figure 1A), Kauk Me is located 15 miles to the east
(Figure 1B), Pyin Oo Lwin (Figure 1C) is located 42
miles to the east, and Wet Won is located 50 miles to
the east of Mandalay (Figure 1D). All patients exhibited
clinical symptoms associated with malaria. Thin and
thick blood smears were prepared from the blood col-
lected from the fingertips of patients for microscopic
examination (magnification 7 × 100). A local health unit
employee read the Giemsa-stained blood smears, and
treatment was administered to those patients who tested
positive for malaria, based on the guidelines of The
Department of Health, the Union of Myanmar. Before
treatment, additional blood samples of approximately 3
ml were collected from each patients whose infection
was confirmed by microscopic examination (n = 52) or
patients who had fever only (n = 60). The blood samples
were transferred to the National Institute of Health,
Korea Centers for Disease Control and Prevention,
Repubic of Korea, for further antibody analysis.
Informed consent was obtained from all patients. The
study protocol was approved by the Department of
Health (Upper Myanmar), the Union of Myanmar.
Indirect fluorescent antibody test
To test for antibodies against malaria, an indirect fluor-
escent antibody test (IFAT) was performed with whole
blood of patients infected with P. vivax or P. falciparum
as described by Sulzer et al [ 2 3 ] .B r i e f l y ,1 0m lo f
malaria parasite-infected blood was collected from
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Page 2 of 7patients by vein puncture. After removing the plasma,
the cells were suspended in phosphate buffered saline
(PBS, pH 7.2) and centrifuged for 5 min at 2,500 rpm.
The supernatant was discarded, the cells were sus-
pended in fresh PBS, and the wash step was repeated
three more times. Finally, an appropriate amount of PBS
was added to maintain the parasitaemia at no less than
1%. The cells were dropped on each well of Teflon-
coated slides which were dried at room temperature for
12 hrs and maintained at -70°C until required. To deter-
mine the antibody titres against P. vivax or P. falci-
parum for each patient, the antigen slides were fixed in
pre-cooled acetone (-20°C) for 10 min and washed with
PBS, and 20 ㎕ diluted sera from 1:32 to 1:8,192 (vol/vol)
was added to each well. The positive and negative con-
trols were dropped on each slide and incubated in a
moisture chamber for 30 min at 37°C. The reactions
were stopped by washing out the reacted sera with PBS.
The slides were immersed in PBS for 6 min and then
dried at room temperature. Diluted FITC conjugated
anti-human IgG or IgM (Sigma, 1:32 vol/vol in PBS)
was added to each well and incubated and washed using
the same method described above. Several drops of buf-
fered glycerol were then added to the samples and cov-
ered with coverslips. The slides were examined under a
40× fluorescence objective.
Enzyme-linked immunosorbent assay
To verify that the blood samples had antibodies against
the CSP VK210 [24] and VK247 subtypes [25], the
Pvs25 [26] and Pvs28 [27] antigens of P. vivax,a n dt h e
PfLSA-1 [28] and PfLSA-3 [29] antigens of P. falci-
parum (developed by the authors), an enzyme-linked
immunosorbent assays were performed with these anti-
g e n s .B r i e f l y ,5 0μl of capture antigen solution (0.5 μg/
ml) was placed in a 96-well plate (Corning, Lowell, MA,
USA) and incubated for 12 hrs at room temperature.
The cells were aspirated and filled with blocking buffer
(1% BSA, 0.05% PBS-Tween 20) and incubated for 1 hr
at room temperature. After washing the wells three
times with 0.05% PBS-Tween 20, the human serum
samples in blocking buffer at a dilution of 1:100 (vol/
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Figure 1 Study areas in Mandalay, Myanmar. A: Sedaw Gyi; B: Kyauk Me; C: Pyin Oo Lwin; D: Wet Won.
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Page 3 of 7vol) were added to each of the wells. The four positive
and four negative control serum samples were also
added to each plate. After a 2-hr incubation at room
temperature, the plates were washed three times with
0.05% PBS-Tween 20 and then the peroxidase-conju-
gated anti-human IgG (Sigma, 1:2,000, vol/vol) diluted
in blocking buffer was added to each well and incubated
again for 1 hr at room temperature. The reaction was
stopped by washing the plates as described above. To
develop the colour, 100 μl2 . 2 ’-azino-di-(3-ethyl-
benzthiozoline-6-sulfonic acid) (ABTS) peroxidase sub-
strate (Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA) was added and incubated for 30 min. The
absorbance of the mixture was measured at 405 nm,
and the cut-off value was taken as the mean + 2 stan-
dard deviations of the negative samples.
Data analysis
The overall proportions of infections diagnosed by each
test method were compared by the Fisher’s exact test.
Data analyses were performed using GraphPad (Graph-
Pad Software, Inc., La Jolla, CA).
Results
Detection of parasites in blood films
Three-millilitre blood samples were taken from patients
who had a fever after making thick and thin smears in
the field. Thick smears were immediately examined by
microscopic examination. The sera were separated from
blood samples and kept frozen for antibody tests. Thin
blood smears were examined in more detail in the
laboratory to confirm the species of parasite. As a result
of the thick smear examination in the field, 14 (12.5%)
patients (n = 112) were found to be infected with P.
vivax and 26 (23.2%) with P. falciparum,a n d7 2w e r e
negative for infection (Table 1). By the thin smear tech-
nique, 23 patients were found to be infected with P.
vivax,1 9w i t hP. falciparum, five with both species, and
65 patients were negative for infection. Based on micro-
scopic examination, blood samples were divided into
two groups: Group I had a positive in thick or thin
blood smear (n = 52), and Group II was negative for
infection in both examinations (n = 60).
Seropositive rates related to P. falciparum infection
When patient sera were analysed by ELISA using the
PfLSA-1 and PfLSA-3 recombinant proteins as antigens,
the positive rates of PfLSA-1 were similar in Group I
(73.1%, 38/52) and Group II (73.3%, 44/60). The positive
rates of PfLSA-3 were not significantly different in
Group I (26.9%, 14/52) and Group II (31.7%, 19/60)
(Table 2, P = 0.6444).
When patient sera were analysed by IFAT using P.
falciparum-infected red blood cells as antigens, the
positive rates of IgG were not significantly different in
Group I (80.8%, 42/52) and Group II (70.0%, 42/60).
The positive rates of IgM were similar in Group I
(21.2%, 11/52) and Group II (23.3%, 14/60) in Group II
(Table 3, P = 0.4986).
Seropositive rates related to P. vivax infection
When patient sera were analysed by ELISA using the
VK210 and VK247 recombinant proteins of P. vivax as
antigens, the positive rates of VK210 were not signifi-
cantly different in Group I (23.1%, 12/52) and in Group
II (40.0%, 24/60). The positive rates of VK247 also were
not significantly different in Group I (9.6%, 5/52) and
Group II (21.7%, 13/60) (Table 4, P = 0.6551).
When patient sera were analysed by IFAT using P.
vivax-infected red blood cells as antigens, the positive
rates of IgG were not significantly different in Group I
(53.8%, 28/52) and in Group II (41.7%, 25/60). The posi-
tive rates of IgM were similar in Group I (28.8%, 15/52)
and in Group II (25.0%, 15/60) (Table 5, P = 0.8661).
When patient sera were analysed by ELISA using
Pvs25 and Pvs28 recombinant proteins as antigens, the
positive rates of Pvs25 were not significantly different in
Group I (19.2%, 10/52) and in Group II (36.7%, 22/60).
The positive rates of Pvs28 were not significantly differ-
ent in Group I (23.1%, 12/52) and Group II (50.0%, 30/
60) (Table 6, P = 0.8503).
Table 1 Detection of malaria parasites by microscopic
examination using thick and thin smears
Type of Examination Pv
(Single)
Pf
(Single)
Pv + Pf
(Double)
3
Negative Total
Thick
1 14 26 0 72 112
Thin
2 23 19 5 65 112
Pv: Plasmodium vivax
Pf: Plasmodium falciparum
1Thick blood smear examination
2Thin blood smear examination
3Patients who are infected with both P. vivax and P. falciparum
Table 2 Positive rates of liver stage-specific antigens of
P. falciparum
Antigen No. Examined No. Positive Positive rate (%)
Group I
1PfLSA-1 52 38 73.1
2PfLSA-3 52 14 26.9
Group II PfLSA-1 60 44 73.3
PfLSA-3 60 19 31.7
1Liver stage-specific antigen-1 of P. falciparum
2Liver stage-specific antigen-3 of P. falciparum
* Significant difference between Group I and Group II results (Fisher’s two-
tailed P = 0.6444).
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Although Myanmar is one of the major malaria endemic
countries and contributes to approximately 60% of
death due to malaria in Southeast Asia [1], the antibody
dynamics against the malaria parasites prevalent in this
county are poorly understood. This study demonstrated
the diversity of several antibodies against P. vivax and P.
falciparum to provide an insight into the dynamics of
malaria transmission, which in turn increases our under-
standing of vaccine application and malaria control in
Myanmar.
More patients were found to be positive for infection
(n = 47) by thin blood smears than by thick blood
smears (n = 40) by microscopic examination; these
results might be explained by spending three times
more time in laboratory conditions. Additionally, it
was much easier to discriminate between P. vivax and
P. falciparum species by thin smear examination.
Therefore, five cases of infection with both species
were detected by thin blood smear examination (Table 1).
Blood was taken from patients who had malaria symp-
toms, and the blood samples were divided into two groups
based on microscopic examination; that is, positive cases
(n = 52) as Group I and negative cases (n = 60) as Group
II. The positive rates as measured by the antibody test
with PfLSA-1 were similar in both groups. Furthermore,
the positive rates of PfLSA-3 was higher in non-patient
Group II than patient Group I (Table 2). However, the
positive rates of IFAT (IgG detection) were higher by
more than 10% in Group I (Table 3). Sero-immunological
diagnosis, in particular by IFAT, is an important tool for
the detection of malaria, especially when microscopic evi-
dence of the parasites is not available due to several rea-
sons [22]. Among those cases that were positive for P.
falciparum infection by microscopic examination, four
were negative for IgG and IgM as detected by IFAT
(7.6%). These patients may not have been exposed to P.
falciparum.
During CSP serotyping of P. vivax, seven individuals
were positive for the VK210 subtype alone, five were
positive for both the VK210 and VK247 subtypes, and
no one was positive for just the VK247 subtype in
Group I. Twelve patients were positive for the VK210
subtype alone, twelve were positive for both the
VK210 and VK247 subtypes, and only one was posi-
tive for the VK247 subtype alone in Group II. In con-
clusion, the positive rates of the VK210 subtype,
dormant form (32.1%, 36/112) was twice that of the
VK247 subtype, variant form (18.1%, 18/112) in
Groups I and II combined (Table 4). Similar to the
IFAT results of P. falciparum,t h ep o s i t i v er a t e so f
IgG of P. vivax in Group I was a little bit higher than
that of Group II (Table 5).
Among the patients positive for P. vivax infection by
microscopic examination, eight patients were negative
for IgG and IgM as detected by IFAT (15.4%). These
patients may have been recently infected by P. vivax.
Notably, the positive rates of transmission-blocking
vaccine candidates in Group II were double those of
Group I (Table 6). The significance of this observation
should be elucidated in the future studies.
Table 3 Positive rates of blood stage-antigens of P.
falciparum
Antibody No. Examined No. Positive Positive rate (%)
Group I IgG 52 42 80.8
IgM 52 11 21.2
Group II IgG 60 42 70.0
IgM 60 14 23.3
* Significant difference between Group I and Group II results (Fisher’s two-
tailed P = 0.4986).
Table 4 Positive rates of Circumsporozoite protein (CSP)
of P. vivax
Antigen No. Examined No. Positive Positive rate (%)
Group I
1VK210 52 12 23.1
2VK247 52 5 9.6
Group II VK210 60 24 40.0
VK247 60 13 21.7
1Isolates that reacted with synthetic peptide carrying the amino acid
sequence [GDRA(D/G)GQPA] of the dominant form of P. vivax CSP.
2Isolates that reacted with synthetic peptide carrying the amino acid
sequence [ANGA(G/D)(N/D)QPG] of the variant form of P. vivax CSP.
* Significant difference between Group I and Group II results (Fisher’s two-
tailed P = 0.6551)
Table 5 Positive rates of blood stage antigens of P. vivax
by IFAT
Antibody No. Examined No. Positive Positive rate (%)
Group I IgG 52 28 53.8
IgM 52 15 28.8
Group II IgG 60 25 41.7
IgM 60 15 25.0
* Significant difference between Group I and Group II results (Fisher’s two-
tailed P = 0.8661).
Table 6 Positive rates of Transmission Blocking Vaccine
candidates of P. vivax
Antigen No. Examined No. Positive Positive rate (%)
Group I Pvs25 52 10 19.2
Pvs28 52 12 23.1
Group II Pvs25 60 22 36.7
Pvs28 60 30 50.0
* Significant difference between Group I and Group II results (Fisher’s two-
tailed P = 0.8503).
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A major finding of our study was that the profile of
antibodies against several malaria antigens, especially
current vaccine candidates, in Myanmar is extremely
complex. These data could be used as fundamental
information for sero-epidemiological studies in Myan-
mar. The geographic location of Myanmar appears to
contribute to the large diversity in serology of P. vivax
and P. falciparum in this country. Only the blood stage
antigens showed high positivity rates in Group I (patient
group) for both P. vivax and P. falciparum. For other
antigens, PfLSA-1 and PfLSA-3 for P. falciparum and
VK210, VK247, Pvs25, and Pvs28 for P. vivax,G r o u pI I
(non patient group) had higher positivity rates than
Group I. Therefore, antibody detection does not in any
way help to support the results of microscopic examina-
tion. A remaining unsolved question in this study is
how the high positivity rate in the non-patient group
prevents the onset of disease. Further studies using
more blood samples are required to define the relation-
ship between antibody production and illness.
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